OpenOnco Handbook

Diffuse large B-cell lymphoma: first-line reasoning

draft hcp_learner en

Deterministic learning chapter over OpenOnco KB entities, synthetic cases, and source records.

Learning objectives

  1. Identify the minimum diagnostic and biomarker inputs needed before first-line DLBCL treatment selection.
  2. Explain how IPI risk, fitness, organ function, and biology influence R-CHOP versus Pola-R-CHP reasoning.
  3. Recognize red flags that do not switch the regimen but must change supportive care or MDT discussion.

At a glance

  • Confirmed histology and CD20 positivity are required before first-line treatment planning.
  • IPI and fitness gates drive the first-line algorithm in OpenOnco.
  • R-CHOP remains the standard track; Pola-R-CHP is modeled as the intensified track for higher-risk disease when accessible.
  • HBV, HCV, HIV, cardiac function, pregnancy, and CNS-risk checks sit beside regimen selection and must not be skipped.
  • This chapter is an OpenOnco-authored learning aid, not official ESMO content or a CME-credit activity.

Diagnostic minimum

The learning path starts after histology confirms DLBCL NOS. The chapter expects a CD20 result, baseline staging, LDH, ECOG/fitness, cardiac function, viral screening, pregnancy status when relevant, and FISH or equivalent testing to rule out high-grade double-hit biology.

Linked entities

DIS-DLBCL-NOSDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifieddiseasesBIO-CD20-IHCCD20 expression (IHC)biomarkersTEST-PET-CTFDG PET/CT (whole body)testsTEST-FISH-PANELFISH (Fluorescence In Situ Hybridization)tests

Section sources

  • SRC-NCCN-BCELL-2025 NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas
  • SRC-ESMO-DLBCL-2024 ESMO Clinical Practice Guideline on Diffuse Large B-Cell Lymphoma

First-line decision logic

OpenOnco models the first-line decision as a standard R-CHOP track and an intensified Pola-R-CHP track. Frailty or organ dysfunction is evaluated before intensification. Higher IPI or high-risk biology can move the learner toward the intensified track if access and contraindications are addressed.

Linked entities

ALGO-DLBCL-1LALGO-DLBCL-1LalgorithmsIND-DLBCL-1L-RCHOPIND-DLBCL-1L-RCHOPindicationsIND-DLBCL-1L-POLA-R-CHPIND-DLBCL-1L-POLA-R-CHPindicationsRF-DLBCL-HIGH-IPIDLBCL with International Prognostic Index ≥2 — selects intensified Pola-R-CHP over R-CHOP per POLARIX evidenceredflagsRF-DLBCL-HIGH-RISK-BIOLOGYHigh-risk biology in DLBCL NOS: double-expressor (MYC + BCL2 by IHC, no rearrangement), TP53 mutation, or non-GCB cell-of-origin in elderly / high-IPI context. Distinct from HGBL "double-hit" which is its own entity (DIS-HGBL-DH) — but double-expressor remains DLBCL NOS and shifts toward intensified backbone. redflags

Section sources

  • SRC-NCCN-BCELL-2025 NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas
  • SRC-ESMO-DLBCL-2024 ESMO Clinical Practice Guideline on Diffuse Large B-Cell Lymphoma
  • SRC-POLARIX-TILLY-2022 Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Common traps

Do not treat regimen selection as the whole task. HBV reactivation prevention, HIV drug interaction review, HCV coordination, CNS-risk assessment, baseline LVEF, and pregnancy screening are parallel obligations. Some of these do not change the selected indication but still change safety planning.

Linked entities

RF-DLBCL-CNS-RISKDLBCL with high CNS-IPI risk (CNS-IPI ≥4) OR specific anatomic sites (testicular, breast, kidney/adrenal, paranasal sinus, bone marrow with high-risk pathology) — triggers CNS prophylaxis pathwayredflagsRF-DLBCL-ORGAN-DYSFUNCTIONBaseline organ dysfunction precluding standard R-CHOP doses: LVEF <50% (anthracycline contraindicated), CrCl <30 mL/min (severe cyclophosphamide / methotrexate dose constraints), bilirubin >3× ULN (vincristine / doxorubicin metabolism), or DLCO <60% (lung-toxicity risk on CHOP-based therapy). redflagsBIO-HBV-STATUSHepatitis B virus statusbiomarkersBIO-HIV-STATUSHIV statusbiomarkers

Section sources

  • SRC-NCCN-BCELL-2025 NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas
  • SRC-ESMO-DLBCL-2024 ESMO Clinical Practice Guideline on Diffuse Large B-Cell Lymphoma

Worked synthetic cases

  • patient_dlbcl_low_ipi Low-IPI newly diagnosed DLBCL - standard-track reasoning, baseline workup completeness examples/patient_dlbcl_low_ipi.json
  • patient_dlbcl_high_ipi High-IPI newly diagnosed DLBCL - intensification trigger, Pola-R-CHP access caveat examples/patient_dlbcl_high_ipi.json

Practice questions

0 of 3 answered · 0 correct

Answers, score, and reasoning tags are kept in your browser session only and clear when you close this tab. Multi-select questions require every correct option (and no extras) for a credit.

Question 1 type_a intro HQ-DLBCL-1L-001

A fit patient has newly diagnosed CD20-positive DLBCL NOS with IPI 0-1 and no major organ dysfunction. In the OpenOnco first-line learning model, which track is the standard default?

Question 2 type_a intro HQ-DLBCL-1L-002

Which missing baseline item most directly blocks safe anthracycline-containing regimen planning in this chapter?

Question 3 type_k intermediate HQ-DLBCL-1L-003

For first-line DLBCL reasoning, which statements are true in the OpenOnco handbook model?